ES3005507T3 - Combination therapy for treating cancer - Google Patents
Combination therapy for treating cancer Download PDFInfo
- Publication number
- ES3005507T3 ES3005507T3 ES21794474T ES21794474T ES3005507T3 ES 3005507 T3 ES3005507 T3 ES 3005507T3 ES 21794474 T ES21794474 T ES 21794474T ES 21794474 T ES21794474 T ES 21794474T ES 3005507 T3 ES3005507 T3 ES 3005507T3
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- azd5305
- pharmaceutically acceptable
- acceptable salt
- carboplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089195P | 2020-10-08 | 2020-10-08 | |
| PCT/EP2021/077703 WO2022074124A1 (en) | 2020-10-08 | 2021-10-07 | Combination therapy for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3005507T3 true ES3005507T3 (en) | 2025-03-14 |
Family
ID=78293953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21794474T Active ES3005507T3 (en) | 2020-10-08 | 2021-10-07 | Combination therapy for treating cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230372333A1 (https=) |
| EP (1) | EP4225297B1 (https=) |
| JP (1) | JP7818585B2 (https=) |
| KR (1) | KR20230083291A (https=) |
| CN (1) | CN116194110B (https=) |
| AU (1) | AU2021356123B2 (https=) |
| BR (1) | BR112023005160A2 (https=) |
| CA (1) | CA3197056A1 (https=) |
| DK (1) | DK4225297T3 (https=) |
| ES (1) | ES3005507T3 (https=) |
| FI (1) | FI4225297T3 (https=) |
| HU (1) | HUE069249T2 (https=) |
| IL (1) | IL301687A (https=) |
| MX (1) | MX2023004156A (https=) |
| PL (1) | PL4225297T3 (https=) |
| PT (1) | PT4225297T (https=) |
| TW (1) | TW202228693A (https=) |
| WO (1) | WO2022074124A1 (https=) |
| ZA (1) | ZA202304965B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| CN118119618A (zh) * | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| US20230250428A1 (en) * | 2022-02-07 | 2023-08-10 | Alliance Of Cardiovascular Researchers | Method and composition for early detection of malignancies |
| IL316019A (en) * | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| CN118973572A (zh) * | 2022-04-07 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| CN121464135A (zh) * | 2023-07-07 | 2026-02-03 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015184145A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| SI3999506T1 (sl) * | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
-
2021
- 2021-10-06 TW TW110137116A patent/TW202228693A/zh unknown
- 2021-10-07 ES ES21794474T patent/ES3005507T3/es active Active
- 2021-10-07 DK DK21794474.3T patent/DK4225297T3/da active
- 2021-10-07 US US18/248,108 patent/US20230372333A1/en active Pending
- 2021-10-07 EP EP21794474.3A patent/EP4225297B1/en active Active
- 2021-10-07 KR KR1020237013320A patent/KR20230083291A/ko active Pending
- 2021-10-07 CN CN202180065599.5A patent/CN116194110B/zh active Active
- 2021-10-07 WO PCT/EP2021/077703 patent/WO2022074124A1/en not_active Ceased
- 2021-10-07 PT PT217944743T patent/PT4225297T/pt unknown
- 2021-10-07 MX MX2023004156A patent/MX2023004156A/es unknown
- 2021-10-07 CA CA3197056A patent/CA3197056A1/en active Pending
- 2021-10-07 JP JP2023521357A patent/JP7818585B2/ja active Active
- 2021-10-07 BR BR112023005160A patent/BR112023005160A2/pt unknown
- 2021-10-07 AU AU2021356123A patent/AU2021356123B2/en active Active
- 2021-10-07 IL IL301687A patent/IL301687A/en unknown
- 2021-10-07 HU HUE21794474A patent/HUE069249T2/hu unknown
- 2021-10-07 FI FIEP21794474.3T patent/FI4225297T3/fi active
- 2021-10-07 PL PL21794474.3T patent/PL4225297T3/pl unknown
-
2023
- 2023-05-04 ZA ZA2023/04965A patent/ZA202304965B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202304965B (en) | 2024-09-25 |
| HUE069249T2 (hu) | 2025-02-28 |
| JP7818585B2 (ja) | 2026-02-20 |
| EP4225297A1 (en) | 2023-08-16 |
| CA3197056A1 (en) | 2022-04-14 |
| BR112023005160A2 (pt) | 2023-04-18 |
| MX2023004156A (es) | 2023-05-03 |
| CN116194110B (zh) | 2025-06-17 |
| DK4225297T3 (da) | 2025-01-02 |
| AU2021356123A1 (en) | 2023-06-08 |
| PL4225297T3 (pl) | 2025-03-17 |
| TW202228693A (zh) | 2022-08-01 |
| KR20230083291A (ko) | 2023-06-09 |
| PT4225297T (pt) | 2024-12-30 |
| AU2021356123B2 (en) | 2025-01-09 |
| WO2022074124A1 (en) | 2022-04-14 |
| FI4225297T3 (fi) | 2024-12-10 |
| IL301687A (en) | 2023-05-01 |
| EP4225297B1 (en) | 2024-10-23 |
| JP2023546362A (ja) | 2023-11-02 |
| CN116194110A (zh) | 2023-05-30 |
| US20230372333A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3005507T3 (en) | Combination therapy for treating cancer | |
| ES2818620T3 (es) | Derivados de azabencimidazol como inhibidores de pi3k beta | |
| ES3036500T3 (en) | Pyrazine derivative as chk1 inhibitor | |
| ES2504690T3 (es) | Compuestos inhibidores de PARP, composiciones y métodos de uso | |
| ES2928169T3 (es) | Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos | |
| ES2895365T3 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa Wee-1 | |
| US11666574B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2008509948A5 (https=) | ||
| JP2023545096A (ja) | 抗体－薬物コンジュゲート及びｐａｒｐ１選択的阻害薬の組み合わせ | |
| CN102824346B (zh) | 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 | |
| AU2007264665B2 (en) | Potentiator of radiation therapy | |
| CN115677824B (zh) | 可诱导sos1蛋白质降解的化合物、制备方法和用途 | |
| CN106459011B (zh) | 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途 | |
| CN111643502A (zh) | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 | |
| ES2760507T3 (es) | Derivados de imidazopiridazina enlazados a heterociclilo como inhibidores de PI3Kß | |
| EA049465B1 (ru) | Комбинированная терапия для лечения рака | |
| HK40099137B (en) | Combination therapy for treating cancer | |
| HK40099137A (en) | Combination therapy for treating cancer | |
| US20180296579A1 (en) | Methods of treating ibrutinib-resistant disease | |
| CN120904168A (zh) | 第四代egfr抑制剂、及其制备方法和在药学上的应用 | |
| BR122024006404A2 (pt) | Compostos inibidores de tirosina e de cdc2 específica de treonina cinase e composição farmacêutica compreendendo os mesmos | |
| WO2025063888A1 (en) | Survivin-targeted compounds | |
| AU2024344247A1 (en) | Survivin-targeted compounds | |
| CN121889380A (zh) | 盐、共晶、其药物组合物以及涉及其的治疗方法 | |
| JP2023526235A (ja) | 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体 |